MIF-IN-5 (compound 1d) is a highly effective and reversible competitive inhibitor of macrophage migration inhibitory factor (MIF), exhibiting an IC 50 of 4.8 μM and a Ki value of 3.3 μM [1].
MIF-IN-6 (compound 2d) is an effective inhibitor of macrophage migration inhibitory factor (MIF), exhibiting an IC50 of 1.4 μM and a Ki value of 0.96 μM. MIF-IN-6 effectively reduces MIF-induced ERK phosphorylation and impedes A549 cell proliferation [1].
MIF degrader MD13 is involved in protein-protein interactions that play key roles in inflammation and cancer. Current strategies to develop small molecule modulators of MIF functions are mainly restricted to the MIF tautomerase active siteMIF degrader MD13. MD13 also exhibits antiproliferative effect in a 3D tumor spheroid model. In conclusion, we describe the first MIF-directed PROTAC (MD13) as a research tool, which also demonstrates the potential of PROTACs in cancer therapy.